Finance

Lists
Why is AKTS up 4,57%?
Dive Deeper
AKTS:NASDAQ
Aktis Oncology Inc
USD 15,80
+4,57%
(+0,69) 1D
20 Okt., 11:13:59 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AKTS...
Open
USD 15,14
High
USD 16,08
Low
USD 15,00
Mkt. cap
849,20 m
Avg. vol.
475,47 k
Volume
95,49 k
52-wk high
USD 34,19
52-wk low
USD 14,72
EPS
-USD 1,42
Shares outstanding
53,75 m
No. of employees
79
Open
USD 15,14
High
USD 16,08
Low
USD 15,00
Mkt. cap
849,20 m
Avg. vol.
475,47 k
Volume
95,49 k
52-wk high
USD 34,19
52-wk low
USD 14,72
EPS
-USD 1,42
Shares outstanding
53,75 m
No. of employees
79
News stories
From web sources and news partners
About Aktis Oncology Inc
CEO-
Employees79
Founded2020
HeadquartersBoston, Massachusetts, Verenigde State van Amerika
Sector-
Analyst ratings
Based on 6 analysts giving stock ratings to AKTS in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for AKTS in the last 3 months.
Highest
Current USD 15,80
USD 40,00 (+153,16%)
Average
USD 35,80 (+126,58%)
Lowest
USD 33,00 (+108,86%)
Analyst
Recommendation
Action
Price target
Projected
Date
David Nierengarten
Wedbush
Buy
Maintained
USD 35,00
+121,5%
10/02/2026
Jeff Jones
Oppenheimer
Buy
Initiated
USD 40,00
+153,2%
09/09/2026
David Lebowitz
BMO Capital
Buy
Initiated
USD 37,00
+134,2%
08/18/2026
Unknown Analyst
BMO Capital
Buy
Initiated
USD 37,00
+134,2%
08/18/2026
Alec Stranahan
Bank of America Securities
Buy
Maintained
USD 34,00
+115,2%
08/14/2026
Jessica Fye
J.P. Morgan
Buy
Reiterated
USD 33,00
+108,9%
08/14/2026
Alexandra Ramsey
William Blair
Buy
Maintained
-
-
08/14/2026
Christopher Raymond
Raymond James
Buy
Initiated
USD 40,00
+153,2%
06/16/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
USD 35,00
+121,5%
06/03/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/11/2026
Sami Corwin
William Blair
Buy
Initiated
USD 18,75
+18,7%
05/02/2026
Unknown Analyst
William Blair
Buy
Initiated
USD 18,60
+17,7%
04/29/2026
Andy Hsieh
William Blair
Buy
Initiated
USD 32,00
+102,5%
04/29/2026
Jonathan Chang
Leerink Partners
Buy
Initiated
USD 31,00
+96,2%
02/03/2026
Last report
13 Aug. 2026
Fiscal period
Q2 2026
-USD 0,44 / -USD 0,43
-2,15%miss
Revenue / Est. (USD)
3,38 m / 2,58 m
+30,99%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Jun. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
1,60 m
1,87 m
3,23 m
3,38 m
Cost of goods sold
18,63 m
16,49 m
20,04 m
25,28 m
Cost of revenue
18,63 m
16,49 m
20,04 m
25,28 m
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,94 m
2,75 m
5,90 m
7,00 m
Operating expense
3,94 m
2,75 m
5,90 m
7,00 m
Total operating expenses
22,56 m
19,24 m
25,93 m
32,28 m
Operating income
-20,96 m
-17,38 m
-22,71 m
-28,90 m
Other non operating income
-20,00 k
-11,00 k
-3,00 k
-10,00 k
EBT including unusual items
-18,08 m
-15,14 m
-18,32 m
-24,14 m
EBT excluding unusual items
-18,08 m
-15,14 m
-18,32 m
-24,14 m
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-18,08 m
-15,14 m
-18,32 m
-24,14 m
Net profit margin
-1 128,98%
-809,52%
-567,86%
-713,48%
Earnings per share
-
-
-0,38
-0,44
Interest and investment income
2,91 m
2,25 m
4,38 m
4,76 m
Interest expense
-
-
-
-
Net interest expenses
2,91 m
2,25 m
4,38 m
4,76 m
Depreciation and amortization charges
-
-
-
-
EBITDA
-20,41 m
-16,68 m
-22,05 m
-28,02 m
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google-programme